"If BoM frustratingly fails for primary, I do believe the pps will tumble initially though down to "stomach ache" levels from the past, but there will still be enough IP, Goodwill, and "potential" for a different track and path to success (probably with a deep pockets BP partner), if there is still promising primary and secondary data but without study endpoints success. "

Yes, I would agree, especially if there is a very positive MOCA score with the Apabetalone treated group. Hence, it makes more sense to hold RVX.WT.A warrants with an expiration date of 2023 over the RVX.WT with an expiration date of 2021.

IMO...Koo